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Abstract
Interpreting Genome-Wide Association Studies (GWAS) at a gene level is an important step towards understanding the
molecular processes that lead to disease. In order to incorporate prior biological knowledge such as pathways and protein
interactions in the analysis of GWAS data it is necessary to derive one measure of association for each gene. We compare
three different methods to obtain gene-wide test statistics from Single Nucleotide Polymorphism (SNP) based association
data: choosing the test statistic from the most significant SNP; the mean test statistics of all SNPs; and the mean of the top
quartile of all test statistics. We demonstrate that the gene-wide test statistics can be controlled for the number of SNPs
within each gene and show that all three methods perform considerably better than expected by chance at identifying
genes with confirmed associations. By applying each method to GWAS data for Crohn’s Disease and Type 1 Diabetes we
identified new potential disease genes.
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Introduction
Genome-Wide Association Studies (GWAS) link genetic vari-
ants to phenotypes. One common study design in human disease
genetics is to compare a group of diseased individuals (cases) to a
group of healthy individuals (controls) for a large number of Single
Nucleotide Polymorphisms (SNPs). The frequency of each allele is
compared between cases and controls using a x
2 statistic, which
can be transformed into a measure for the probability of the data
arising under no association between disease and SNP (p-value).
Currently, GWAS are carried out using microarray technology,
genotyping up to one million SNPs in parallel. Because a statistical
test is performed for each SNP, careful multiple hypothesis testing
procedures are employed to ensure the identification of association
signals with genome-wide significance, typically with a p-value
p,5N10
28 [1]. In most GWAS only a few SNPs pass this cor-
rection and although this approach has led to the discovery of
several novel disease-linked variants, it ignores thousands of SNPs
with ‘‘suggestive’’ p-values that fail to reach the stringent threshold
for genome-wide significance, but may reflect evidence for associa-
tion. Several approaches try to make use of these ‘‘suggestive’’
p-values through the incorporation of prior biological knowledge
[2,3,4,5,6,7,8,9,10,11,12]. The best known is Gene Set Enrich-
ment Analysis (GSEA) [3,13], which assesses whether predefined
sets of genes are overrepresented within a sample. Genes that are
members of the same gene-set are typically involved in a common
biological process as defined by e.g. the Gene Ontology [14] or
biological pathways as defined by databases such as KEGG [15].
In a similar way, protein networks have been consulted [10,11]
with the objective of identifying subnetworks of interacting pro-
teins. Individually none of the proteins within such a subnetwork
might be significantly associated, but overall a subnetwork might
show statistically significant association with a disease.
All of these studies face very similar methodological problems:
GWAS report association for individual SNPs, whereas functional
information typically exists for proteins or genes. Therefore SNPs
have to be assigned to genes and their individual association
signals combined. This can be done in different ways and one must
take into consideration that the number of SNPs per gene can vary
to a great extent. The most widely used approach is to take the
most significant p-value per gene [2,3,4,5,6,7,8]; however this can
introduce a substantial bias in the downstream analysis if the
number of SNPs per gene is not controlled for [9]. In this work we
systematically compare three methods to analyse GWAS data at
the gene level. We also propose a way to control for differences in
the number of SNPs per gene based on permutations of the disease
status and demonstrate its effectiveness. Based on GWAS data for
Crohn’s disease (CD) and Type 1 Diabetes (T1D) genotyped by
the Wellcome Trust Case Control Consortium [16], we evaluate
the performance of the different methods using sets of disease
genes that were identified and replicated by the most recent meta-
analyses [17,18].
Methods
Quality Control and Association Testing
GWAS of seven diseases have been performed by the WTCCC
[16]. Approximately 3,000 shared controls and 2,000 cases were
genotyped for seven diseases, including Crohn’s Disease (CD) and
Type 1 Diabetes (T1D), on the Affymetrix GeneChip 500K
Mapping Array Set. We re-analyzed the WTCCC I data using
PLINK v1.06 [19]. In addition to SNPs and individuals in the
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stringent quality control criteria than the original study, because
our analysis includes moderate associations which are more sus-
ceptible to study biases. Based on the pooled case/control dataset
we excluded SNPs with Hardy-Weinberg equilibrium p,0.001, a
minor allele frequency of less than 0.01 or genotyping call-rates
of less than 0.97. Association testing was performed using the
Cochran Armitage trend test (1df). We manually checked the most
strongly associated SNPs for every disease to ensure consistency
with the original WTCCC I results. To take into account inflated
test statistics caused by population stratification we corrected test
statistics using the genomic control metric lmedian [20]. The
estimated lmedian (for simplicity denominated as l) for CD
(l=1.12) and T1D (l=1.06) are in good agreement with the
original values reported by the WTCCC (l=1.11 and l=1.05 for
CD and T1D, respectively). For both diseases, 500,000 permuta-
tions of the disease status were performed using the PLINK
max(T) permutation method and association p-values were cal-
culated. Table 1 summarises the GWAS data analysis for CD and
T1D.
To further assess the effect of population stratification on our
analyses we performed principal component analysis (PCA) of
the CD and T1D data using EIGENSTRAT [21]. We then
performed association testing using logistic regression to incorpo-
rate the first two principal components as covariates. For both
diseases, 1,000 permutations of the disease status were performed
using logistic regression and the PLINK max(T) permutation
method.
Gene to SNP assignment
A tab-delimited text-file (seq_gene.md) containing genomic
coordinates for all genes was downloaded from the NCBI ftp-
server [22] in November 2009. Only entries for the human
reference sequence (NCBI assembly GRCh37) and protein-coding
genes were retained. Genes mapping to sex-chromosomes, the
mitochondrial chromosome, unassembled contigs or alternative
haplotypes were discarded. SNPs on the GeneChip 500K Map-
ping Array Set were assigned to the remaining genes. Because this
genotyping platform is based on the previous assembly of the
human genome (NCBI 36) all SNP positions were converted to the
latest assembly using the ‘‘Lift-Over’’ tool on the GALAXY
website [23]. SNPs were assigned to a gene if they are located
within its primary transcript or 40 kilobases (kb) upstream or
downstream. These boundaries are chosen based on the dis-
tribution of association signal with respect to protein-coding genes
[24]. When a SNP could be assigned to multiple genes because of
overlapping flanking windows, the closest gene was chosen.
The WTCCC study found the strongest association signal for
Type 1 Diabetes (T1D) within the Major Histocompatibility
Complex (MHC) region on chromosome 6. The MHC region has
high levels of linkage disequilibrium (LD) and harbours many
genes. This causes the association signal to be spread over many
genes, thereby artificially inflating the number of genes with
associated SNPs. We therefore excluded the MHC region (chro-
mosome 6, position 25,930,839 to position 33,495,825, NCBI
assembly GRCh37) in all analyses of the T1D dataset, which
removed 1,473 SNPs and 185 genes. In total, approximately
290,000 SNPs were assigned to 17,000 protein coding genes.
Table 1 summarises the SNP to gene assignment for CD and
T1D.
Assessment of LD on SNP to gene assignment
In order to assess the effect of LD we repeat our analyses, but
take into account LD to extend the assignment of SNPs to genes.
We use PLINK v1.06 [19] to obtain a list of SNP pairs in LD
(r
2.0.8) based on the GWAS data for CD and T1D [16]. SNPs
are added to the initial assignment if they are in LD (r
2.0.8) with
a SNP in a gene or its 40 kb flanking windows, including SNPs
that have already been assigned to other genes. Taking into
account LD adds approximately 6,000 (2%) additional SNPs to the
analyses.
Deriving a gene-wide test statistic for each gene
Each gene has n SNPs assigned to it with n M N0. Let the test
statistics in the gene be Ti,i=1,…n. Under the null hypothesis of
no association, Ti has a x1
2 distribution (x
2 distribution with one
degree of freedom); high values of Ti indicate evidence for
association. To obtain a gene-wide test statistic, we use three
summary statistics for Ti:
1. maxT: the maximum value of Ti (maximum x1
2 value) for
each gene is chosen;
2. meanT: the arithmetic mean test statistic (mean x1
2 value) for
each gene is calculated;
3. topQ: the highest quartile of all test statistics Ti (highest
quartile of all x1
2 values) in a gene are selected and their mean
is calculated. If n is not a multiple of 4 the number of SNPs
considered for topQ is rounded up to the next integer (e.g. if a
gene has 5 SNPs the mean of the largest two test statistics is
calculated).
Deriving an empirical p-value (pemp) for each gene
We derive test statistics for each gene in the observed dataset
and in 500,000 randomised datasets derived from permutations of
the disease status. For each gene we tabulate the number of
permuted data sets in which we observe a higher gene-wide test
statistic than in the observed data set, thus deriving an empirical p-
value pemp.
Because we compare observed and permuted test statistics for
every gene, a significantly associated gene requires a pemp value that
is also controlled for the number of genes tested. Assuming there
are approximately 20,000 protein-coding genes in the human
genome, a Bonferroni correction requires a p-value threshold of
pemp =0.0561/20,000 =2.5610
26. In order to be able to obtain
Table 1. Overview statistics of the analysed GWAS datasets
and the gene to SNP assignment for Crohn’s Disease (CD) and
Type 1 Diabetes (T1D).
CD T1D
Number of cases before QC 2,009 2,000
Number of cases after QC 1,752 1,964
Number of controls before QC 3,004 3,004
Number of controls after QC 2,938 2,938
Genomic Control metric l 1.12 1.06
Protein-coding genes on chromosome 1–22 20,919 20,919
Protein-coding genes after SNP to gene assignment 17,006 17,006
Protein-coding genes after QC 16,326 16,146
SNPs on the Affymetrix GeneChip 500K Mapping Array Set 500,568 500,568
SNPs assigned to genes (chromosome 1–22) 290,571 289,098
SNPs assigned to genes after QC 227,418 225,973
doi:10.1371/journal.pone.0020133.t001
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the disease status. Empirical p-values are derived for each gene for
all three methods to derive gene-wide test statistics.
Uncontrolled vs. empirical p-value
To compare the different methods we rank genes for each gene-
wide test statistic method. This is done before and after deriving
pemp values (i.e. controlling for the number of variants per gene and
LD) resulting in six different sets of ranks. When pemp values are
identical for two or more genes we use the gene-wide test statistics
to resolve ties. Based on the ranks we calculate pairwise Spearman
rank correlation coefficients between all six sets for the top 500
genes: For each gene, we sum the ranks across all six gene sets, and
select the 500 genes with the highest summed ranks.
To analyse the effect of deriving pemp values for individual genes
we convert the gene-wide test statistics to p-values assuming test
statistics have a x1
2 distribution. For each gene the uncontrolled
p-value is plotted against the pemp value for all three methods.
Table 2. Replicated Disease Genes for Crohn’s Disease from [17] and their ranks for each method.
Rank of gene for
hgnc Number of SNPs per gene n rank maxT rank meanT rank topQ
NOD2 13 1 3 2
ATG16L1 11 2 1 1
IL23R 21 3 4 3
NKX2-3 26 5 5 5
PTPN2 20 7 11 10
IRGM 58 2 6
ZNF365 91 18 149 67
GCKR 63 1 8 1 7 6
CREM 12 34 59 46
C13orf31 6 43 136 78
IL12B 14 55 45 94
SP140 18 64 110 56
CDKAL1 127 83 486 248
C11orf30 22 336 164 180
VAMP3 1 357 356 348
CCR6 14 602 291 319
DNMT3A 9 612 667 399
MTMR3 23 827 788 715
FADS1 3 980 921 1002
NDFIP1 19 1020 754 506
TAGAP 4 1169 3445 1203
IKZF3 8 1192 4281 995
DENND1B 22 1337 3818 1855
THADA 59 1500 1157 1206
JAK2 17 2074 3065 3038
PTGER4 4 2620 4084 2622
PTPN22 4 3457 2465 3498
SMAD3 42 4071 11565 9918
CPEB4 21 4108 4080 3842
ICOSLG 5 6041 8465 6570
PRDM1 18 6151 4859 5241
IL2RA 20 6698 8568 5229
BACH2 49 8022 3687 2962
MAP3K7IP1 6 8040 6149 6685
PLCL1 56 8317 3347 3754
ICAM3 2 9345 9596 9415
UBE2D1 4 10217 12176 10212
TNFSF11 21 11858 9547 9927
ZMIZ1 72 14061 5704 9596
doi:10.1371/journal.pone.0020133.t002
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To assess the performance of the three methods for deriving pemp
values we calculate Receiver Operating Characteristic (ROC)
curves, which estimate the accuracy of a prediction by comparing
the True Positive Rate (TPR = True Positives/Positives) with the
False Positive Rate (FPR = False Positives/Negatives) [25]. In this
analysis we used as positives a list of successfully replicated disease
genes from meta-analyses of T1D [18] and CD [17]. We only
chose loci that either contain a single gene or a for which a unique
candidate gene has been proposed [17,18]. This results in 39 and
27 true positive genes for CD and T1D, respectively (Tables 2, S1
and S2). We assume that all other genes are negatives. We rank all
genes within both lists (positives and negatives) by their pemp values,
and used their gene-wide test statistics to resolve ties when pemp
values are identical for two or more genes. For each gene the
relative rank within the positives is plotted against the relative rank
within the negatives to derive the ROC curve, and the areas under
the curve (AUC) were calculated.
All scripts written for the analyses presented are available from
authors upon request.
Results
Number of SNPs per gene
The Affymetrix 500K GeneChip includes approximately
500,000 SNPs distributed over the whole genome. We assign
these SNPs to their closest protein-coding gene if a SNP is located
less than 40 kb from a gene. Approximately 290,000 SNPs were
assigned to genes, of which 227,000 were left after QC for specific
disease data sets (Table 1). Genes vary substantially in size, which
leads to different numbers of SNPs assigned to each gene (Figure 1).
Of 20,919 protein-coding genes 17,006 have at least one SNP
assigned; most of these genes (,77% or 13,083 genes) have fewer
than 10 SNPs; 6.5% (1,097 genes) have more than 50 SNPs. The
largest number of SNPs assigned to a single gene is 1,008 (CSMD1,
gene length: 818 kb).
We performed analyses of GWAS data for both Crohn’s Disease
(CD) and Type 1 Diabetes (T1D). In the following section we
present results for CD. Results for T1D are comparable and
presented in supplementary material.
Deriving a gene-wide test statistic for each gene
To measure association of a SNP with the disease we compare
genotype frequencies between cases and controls and calculate a
genomic control-corrected test statistic based on an Armitage
trend test for every SNP. To obtain a gene-wide measure of
association we first derive three summary statistics: maxT (the
maximum test statistic for each gene), meanT (the mean test
statistic for each gene), and topQ (the mean of the highest quartile
Figure 1. Distribution of the number of SNPs assigned to
genes. We assigned SNPs on the Affymetrix 500K genotyping array to
protein-coding genes. SNPs were assigned to a gene if they are located
within the transcribed region or within a 40 kilobase flanking window
around the transcribed region. Where flanking windows overlapped
SNPs were assigned to their closest gene only.
doi:10.1371/journal.pone.0020133.g001
Figure 2. Confounding effect of the number of SNPs per gene
(Crohn’s Disease). Multiple test statistics are combined for each gene
using three different methods (maxT, meanT, topQ). For each method,
the gene-wide test statistic is correlated with the number of SNPs per
gene. For these histograms, genes are binned according to their gene-
wide test statistic (left axis). The red dots show the mean number of
SNPs per gene for every bin (right axis).
doi:10.1371/journal.pone.0020133.g002
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summary statistic is subject to confounding factors that have to be
controlled for. The gene-wide test statistic is correlated with the
number of SNPs per gene, n (Figures 2 and S1), as follows.
N For maxT the test statistic increases approximately linearly
with n (Pearson correlation coefficient r=0.36). Even if there is
no association, genes with many SNPs assigned are more likely
to have a SNP with a high test statistic, by chance.
N A different effect occurs for meanT, whereby genes with
many SNPs tend to have gene-wide test statistics close to one,
whereas genes with few SNPs tend to be at the extremes of the
distribution, i.e. to have either very low or very high gene-wide
test statistics. Under the null hypothesis of no association, the
test statistic has a x1
2 distribution, with a mean of 1. When
calculating meanT, genes with more SNPs are therefore likely
to have gene-wide test statistics close to 1, whereas genes with
few SNPs are more affected by individual SNPs with extreme
test statistic.
N An effect similar to meanT is observed for topQ: Genes with
fewer SNPs tend to have extreme gene-wide test statistics
whereas genes with many SNPs tend to have a gene-wide test
statistic close to x
2<3. This value is higher than for the meanT
method since only the top 25% of SNPs per gene are selected.
Deriving an empirical p-value for each gene
The distribution of the summary statistics for each gene is not
known and impossible to derive analytically, since it depends on
the pattern of LD within each gene. We therefore derive an
empirical p-value pemp for each gene from permuted datasets (see
Methods). By comparing the observed to the permuted test
statistics we maintain LD structure and account for differences in
the number of SNPs per gene. The observed pemp values are
appropriately controlled for the number of SNPs per gene; we
observe no correlation between the number of SNPs per gene and
the pemp value (Figures 3 and S2). For each of the three methods to
combine test statistics, the pemp values are approximately uniformly
distributed. The high proportions of very low pemp values (Figures 3
and S2) are likely due to true association signal.
Uncontrolled vs. empirical p-value
Although different methods yield different levels of association
for a given gene, the results are correlated. Between the three
methods to derive pemp values, we observe an average Spearman
rank correlation coefficient of 0.74 when considering the top 500
genes (Tables S1 and S2). The average Spearman rank correlation
coefficient between the three methods before deriving pemp values
(i.e. controlling for the number of variants per gene and LD) is
only 0.30, which reflects the different biases introduced by the
methods to derive gene-wide test statistics
The pemp values are controlled for the number of SNPs per gene
and the correlation structure, but how does the control affect
individual genes? To address this question, we convert the
combined test statistics to p-values assuming test statistics have a
x1
2 distribution. These uncontrolled p-values are plotted against
the pemp values for all three methods (Figures 4 and S3):
N For the maxT method, genes with many SNPs (large n) are
more likely to have a high test statistic and therefore a low
uncontrolled p-value. When deriving pemp values we control for
n. The control has very little impact on genes with n=1 and in
that case the empirical and the uncontrolled p-values are very
similar (lying along the diagonal in Figures 4 and S3). For
genes with higher n the control is stronger and pemp values are
higher than the uncontrolled p-values.
N For meanT we observe a sigmoid-like distribution. That is
explained by the effect of varying n: We compare permuted to
observed test statistics. If there is no association the expected
test statistic is 1. Therefore the expected meanT values for the
permuted datasets are 1, i.e. with increasing n the permuted
meanT is more likely to be 1. For genes with large n this leads
to extreme pemp values when we compare observed to the
permuted meanT. As a result the distribution for genes with
large n shows a stronger curvature than for genes with small n.
When the observed meanT value is 1 (uncontrolled p-value
Figure 3. Distribution of empirical p-value (pemp) for Crohn’s
Disease from 500,000 permutations of the disease labels. Genes
were assigned to 50 bins according to their pemp. Histogram shows the
number of genes with pemp values (left axis). The red line shows the
mean number of SNPs per gene for every bin (right axis). In contrast to
the gene-wide test statistics we observe no correlation of the number
of SNPs per gene with pemp for any method. We observe an increase of
genes with very low pemp values caused by the actual association signal.
doi:10.1371/journal.pone.0020133.g003
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the points representing genes with different n overlap at
meanT=1.
N The distribution for topQ is similar to maxT, but the gradient
for genes with many SNPs is less steep.
Performance
To assess the performance of the different methods of com-
bining test statistics we plot Receiver Operating Characteristic
(ROC) curves for CD and T1D (Figure 5) using two sets of
confirmed disease genes [17,18] under the assumption that all
other genes are not associated (see Methods). The known disease
genes are based on meta-analyses CD [17] and T1D [18]. Based
on genomic loci that successfully replicated the authors selected
the most likely candidate gene considering known involvement in
the immune system, association with other auto-immune disorders
and location of the most strongly associated SNP. Although the
resulting gene list may contain genes which are not associated with
the trait, it is the best currently available dataset to assess the
performance of our methods for measuring genetic association at
the gene-level.
All three pemp methods give considerably better results than
expected by chance. For both diseases the topQ method performs
slightly better than maxT and meanT, although all three methods
perform similarly with differences in the areas under the curve
(AUC) of less than 2%. The performance of the different methods
for the two diseases might depend on the number of SNPs assigned
to the known disease genes. For genes with many SNPs the
association signal can get diluted, as it is the case for the CD
disease gene ZNF365, which has 91 SNPs (Table 2). Its maxT is
23.74 which corresponds to pemp=0.0001, but the meanT and
the topQ for this gene are 2.46 (pemp =0.0041) and 8.32
(pemp=0.0010), respectively. Consequently the performances
measured here by the AUCs depend on the properties of the
known disease genes and we can only assume that they are
characteristic for disease genes that have not been identified yet.
Several known disease genes were consistently ranked very low
by all three methods (Table 2). For some of these genes the
associated SNPs are over 40 kb from the gene (e.g. PTPN22), or
the associated SNP is located in the adjacent gene (e.g. ORMDL3).
Other confirmed disease genes were ranked low because the
associated SNP has not been genotyped by the WTCCC (e.g.
JAK2) or did not show any association (e.g. PLCL1).
Linkage Disequilibrium
Our analysis is influenced by linkage disequilibrium (LD) and
some of the top ranked genes (Table 3) are part of the same LD
region, reflecting the fact that a true association signal could
extend over a large region of the genome if it falls into a large LD
block. Most of the SNPs in such a region would appear to be
associated with the phenotype which can result in several genes
with significant empirical p-values. For example, CYLD and
SNX20 have pemp values smaller than 5.4610
25; they are located
upstream and downstream of NOD2 and are located in the same
Figure 4. Empirical p-values vs. uncontrolled p-values (Crohn’s
Disease). For each gene the pemp is plotted against the uncontrolled p-
value (based on the gene-wide test statistic). Each point represents a
gene and is coloured according to the number of SNPs assigned to a
gene (n). Genes with few SNPs have pemp values similar to the
uncontrolled p-value and therefore cluster along the diagonal. For
genes with higher number of SNPs the distribution depends on the
method to combine test statistics.
doi:10.1371/journal.pone.0020133.g004
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of the confirmed association of the NOD2 gene [26,27,28]. To
further assess the impact of LD on our analyses we extended the
initial gene to SNP assignment. In addition to SNPs located within
the gene or a 40 kb flanking window we include SNPs in LD
(r
2.0.8) with any SNP in this region. This increases the average
number of SNPs per gene to 15.5 (from 13.9) and the total number
of SNPs assigned to genes to over 296,000 (from 290,000) (Figure
S4). Including LD in the gene to SNP assignment has only a
moderate effect: Although AUC values show a small increase for
each method (,1.3%), only a small minority of genes is affected
(Figure S5). Gene ranks obtained with and without taking into
account LD are highly correlated (Spearman rank correlation
r=0.98 for each method and disease). Only 3 genes out of the top
100 have a rank above 100 when including LD (maxT for CD)
and all genes discussed here and shown in the tables only
marginally change their rank or p-value.
Population Stratification
Our primary analysis method is testing for association with the
Cochran Armitage Trend Test, with genomic control correction for
population ancestry, as this makes performing large numbers of
permutations computationally tractable. To assess the effect of
population stratification on our analysis in more detail we per-
formed Principal Component Analysis [21] for both datasets. We
repeated association testing using logistic regression and adjusting
for the firsttwoprincipal components (PC-correction). Thisreduced
thegenomic controlmeasureforCDfroml=1.12tol=1.08,with
no reduction observed for T1D (l=1.06). Adjusting for up to 10
PCs did not reduce l any further. The correlation between gene
ranks of our primary analysis and after correction for population
stratification was high (CD-maxT R=0.932, CD-meanT R=
0.942, CD-topQ R=0.940, T1D-maxT R=0.997, T1D-meanT
R=0.998, T1D-topQ R=0.998). Gene ranks for CD are more
affected than for T1D: out of the top 100 genes of our primary
analysis,78 arewithinthe top 100 genesafterPC-correction,and all
100 are within the top 204 genes (maxT, Figure S6). For T1D, 86
out of the top 100 genes of our primary analysis are within the top
100 after PC-correction and all 100 are within the top 143 genes
(maxT, Figure S6). Correcting for two principal components only
marginally affects the performance of our methods: AUC values
increased by ,0.6% for both CD and T1D.
Associated Genes
All genes discussed here only marginally change their rank or p-
value after correcting for two principal components or when
considering LD for the SNP to gene assignment. For CD we find 7
out of 39 known disease genes (true positives) within the top 30
genes when we rank all genes based on pemp values (derived from
maxT). We use their gene-wide test statistics to resolve ties when
pemp values are identical for two or more genes (Table 3). The genes
STAT3 (maxT rank 27) and SBNO2 (maxT rank 26) are located
within known disease loci, but are not part of the true positive list
because the association signal extends over several genes [17].
Both loci did not reach genome-wide significance in the original
WTCCC study and their association was only confirmed in a
more recent large-scale meta-analyses. STAT3 and SBNO2 can be
linked to the IL10/STAT3 anti-inflammatory pathway [29], which
has been implicated with CD [2,17,30].
Another promising candidate for CD might be DAG1 (dystrog-
lycan 1), ranked 23rd for maxT. It is located within a large LD
block whose association has been replicated and that encompasses
about 35 genes [17]. DAG1 is a cell surface receptor which is used
by several known pathogens [31,32] and there has been spe-
culation about a role for DAG1 in the uptake of Mycobacterium avium
ssp. paratuberculosis and the aetiology of Crohn’s Disease [33].
For T1D five out of 27 known disease genes are within the top
30 (based on maxT, Tables S3 and S4). Of the top 30 genes, 14 fall
into a large LD region on chromosome 12 (position 111,348,628
to position 112,947,717), which contains 15 genes. According to
Todd et al. [34] the most probable causal gene for this region is
SH2B3. The authors detected a highly associated non-synonymous
SNP in exon 3 of SH2B3, which had not been genotyped in the
WTCCC study [16]. Two SNPs that were genotyped in the
WTCCC are assigned to SH2B3 and show moderate association
(p=3610
25 and p=7610
24). Since 40 other SNPs in the region
show stronger association, SH2B3 is only ranked 26 (by maxT).
Figure 5. Receiver Operating Characteristic (ROC) curves for Crohn’s Disease (CD) and Type 1 Diabetes (T1D). To assess the
performance of different methods to combine test statistics we plot the proportion of confirmed disease genes (True Positive Rate) against their rank
within the whole set of genes (False Positive Rate).
doi:10.1371/journal.pone.0020133.g005
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Based on GWAS data for two common diseases we present
three different methods to combine individual test statistics at a
gene level. For all methods the gene-wide test statistic is correlated
with the number of SNPs per gene. Based on permutations of the
disease status we derive an empirical p-value for each gene and
show that it is controlled for the number of SNPs within the gene.
To assess the performances of the pemp m e t h o d sw ed e r i v eR O C
curves based on two sets of disease genes that were replicated
in the most recent meta-analyses [17,18]. The pemp methods
distinguish different genetic architectures underlying a disease: for
maxT a single mutation within a gene contributes to the disease
(i.e. one SNP within a gene shows association); for meanT muta-
tions spread all over the gene contribute to the disease (i.e. all or
many SNPs within a gene show association): in the case of topQ
only a few mutations within a gene contribute to the disease (i.e. a
subset of the SNPs within a gene show association). All three
methods performed substantially better than expected by chance
at identifying these genes, thus justifying our approach. The
performances of the three methods were similar, demonstrating
the robustness of the permutation approach. This is also reflected
by the correlations between empirical p-values for each method
for the top 500 genes. For some genes however, results can vary
across the methods, as illustrated by ZNF365 (Table 2). To
identify all potentially associated genes, results from all methods
should be considered. As the methods are correlated, integration
results in a moderate increase in the number of genes. For
example, the union of the top 500 genes for all three methods
consists of 678 genes.
In this work we perform gene-wide analyses on two indepen-
dent GWAS datasets. We observe the same overall properties for
gene-wide test statistics and pemp-values. Furthermore for both
datasets our methods successfully reproduced known disease asso-
ciations showing the robustness of our approach. In addition to the
methods presented here other methods have been proposed,
including multi-marker association tests [35,36,37,38] and varia-
tions [39,40,41] of Fisher’s method to combine p-values [42].
Recently, two studies proposed approaches to control for con-
founding factors (e.g. number of SNPs per gene) which do not
Table 3. The top 30 ranked genes for Crohn’s Disease (CD) using the maxT method.
HGNC symbol Chr location Region (Mb) n p-value maxT p-value meanT p-value topQ rank maxT rank meanT rank topQ
C1orf141 1p31 67.56-67.59 26 2.0E-06 8.7E-04 6.0E-06 9 60 9
IL23R 1p31 67.63-67.73 21 .2.0E-06 .2.0E-06 .2.0E-06 3 4 3
IL12RB2 1p31 67.77-67.86 17 6.0E-06 1.4E-03 6.8E-04 10 76 54
ATG16L1 2q37 234.16-234.20 11 .2.0E-06 .2.0E-06 .2.0E-06 2 1 1
USP4 3p21 49.31-49.38 5 2.1E-04 1.0E-04 1.1E-04 28 22 23
TCTA 3p21 49.45-49.45 2 1.1E-04 2.0E-06 1.1E-04 21 8 22
AMT 3p21 49.45-49.46 3 7.1E-05 2.0E-06 7.1E-05 19 7 17
DAG1 3p21 49.51-49.57 4 1.2E-04 2.4E-05 1.2E-04 23 14 24
BSN 3p21 49.59-49.71 13 1.6E-05 2.9E-04 1.6E-05 13 32 13
APEH 3p21 49.71-49.72 1 7.3E-05 7.3E-05 7.3E-05 20 19 18
IP6K1 3p21 49.76-49.82 1 2.2E-04 2.2E-04 2.2E-04 29 27 31
SLC22A5 5q31 131.71-131.73 9 1.4E-05 3.3E-04 1.4E-05 12 35 12
C5orf56 5q31 131.75-131.80 13 2.0E-05 4.0E-06 6.0E-06 15 10 8
IRGM 5q33 150.23-150.23 5 .2.0E-06 .2.0E-06 .2.0E-06 8 2 6
ZNF300 5q33 150.27-150.28 10 .2.0E-06 2.0E-06 .2.0E-06 6 9 7
TRIM10 6p21 30.12-30.13 2 1.9E-04 6.6E-04 1.9E-04 25 51 26
HLA-DQB1 6p21 32.63-32.63 11 2.8E-05 3.8E-04 2.1E-04 16 39 29
HLA-DQA2 6p21 32.71-32.72 29 1.1E-04 1.2E-05 1.6E-05 22 12 15
C7orf33 7q36 148.29-148.31 13 2.4E-04 4.6E-04 1.0E-04 30 42 21
LOC100130652 10p15 3.87-3.87 24 1.4E-04 8.8E-02 4.1E-02 24 1,600 809
ZNF365 10q21 64.13-64.43 91 5.8E-05 4.1E-03 9.6E-04 18 149 67
NKX2-3 10q24 101.29-101.30 26 .2.0E-06 .2.0E-06 .2.0E-06 5 5 5
SNX20 16q12 50.70-50.72 3 1.2E-05 5.4E-05 1.2E-05 11 17 11
NOD2 16q12 50.73-50.77 13 .2.0E-06 .2.0E-06 .2.0E-06 1 3 2
CYLD 16q12 50.78-50.84 16 .2.0E-06 .2.0E-06 .2.0E-06 4 6 4
STAT3 17q21 40.47-40.54 13 2.1E-04 2.0E-04 8.5E-05 27 26 19
PTPN2 18p11 12.79-12.88 20 .2.0E-06 7.9E-06 6.0E-06 7 11 10
SBNO2 19p13 1.11-1.17 3 2.0E-04 1.9E-04 2.0E-04 26 24 27
RSHL1 19q13 46.30-46.32 1 1.6E-05 1.6E-05 1.6E-05 14 13 14
ZGPAT 20q13 62.34-62.37 1 3.4E-05 3.4E-05 3.4E-05 17 15 16
Genes are ordered by chromosome and genomic position; n denominates the number of SNPs per gene. The last three columns show the corresponding ranks fort h e
three methods. italics: genes that are within the true positive list.
doi:10.1371/journal.pone.0020133.t003
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to determine how these methods compare.
An open problem that still has to be addressed is the effect of
LD. Correlation between the SNPs of a gene can impact the
combined test statistic for meanT and topQ method. Because
multiple associations can be caused by a single causal SNP a high
meanT or topQ might not reflect several independent associa-
tions. Correlation between the SNPs of a gene can therefore
change the nature of the method to combine test statistics.
Furthermore LD makes it difficult to allocate association signal to
the correct gene. A number of groups have proposed computa-
tional approaches to prioritize genes within LD blocks [6,44,45].
They have been shown to give reasonably good results and could
be combined with our approach.
Another approach is to use imputed genotypes, which will
increase the density of SNPs and therefore the proportion of genes
that are captured. Hong et al. [9] were able to include over 800
additional genes (5%) in their gene-wide analysis of GWAS data,
but levels of statistical significance for most other genes remain
unchanged compared to using genotyped SNPs only. Assigning
SNPs to genes is not straight forward as regulatory elements such
as enhancers can be many kilobases away from the transcribed
region. In addition some disease-associated variants are located in
so-called gene deserts that cannot be linked to protein-coding
genes or any other functional elements. Ultimately functional
studies are necessary to determine which gene is implicated in a
disease process. The methodology demonstrated here is instru-
mental in automatically identifying the relevant genes that might
be implicated in inherited disorders and provides an unbiased
ranked list of genes for experimental validation.
Currently GWAS are moving from microarray based technol-
ogy towards next-generation sequencing (NGS). NGS, in princi-
ple, allows for the identification of all genetic variants. As the
number of genetic variants in a given individual is far higher [46]
than the number of SNPs genotyped using microarray technology,
the number of tests is going to increase dramatically. There is a
need for new analytical methods that combine association signals
over several genetic variants or all variants within a gene, par-
ticularly for rare variants which may individually lack power to
show significant association. Testing for combined association of
all rare variants within a gene overcomes this problem, as
demonstrated for simulated data and sequence data of previously
known disease genes [47,48,49].
With the emergence of next-generation sequencing, GWAS will
increasingly be analysed on gene level. Gene-level association
measurements allow the application of gene-set enrichment analysis
and related methods, which will ultimately improve the under-
standing of the underlying molecular mechanism. The methods
proposed here provide an accurate and powerful approach to
summarise evidence for association within genes and could be used
to design functional follow-up studies.
Supporting Information
Figure S1 Confounding effect of the number of SNPs per
gene (Type 1 Diabetes). Multiple test statistics arecombined for
each gene using three different methods (maxT, meanT, topQ). For
each method, the gene-wide test statistic is correlated with the
number of SNPs per gene. For these histograms, genes are binned
according to their gene-wide test statistic (left axis). The red dots
show the mean number of SNPs per gene for every bin (right axis).
(TIFF)
Figure S2 Distribution of empirical p-value (pemp) for
Type 1 Diabetes from 500,000 permutations of the
disease labels. Genes were assigned to 50 bins according to
their pemp. Histogram shows the number of genes with pemp values
(left axis). The red line shows the mean number of SNPs per gene
for every bin (right axis). In contrast to the gene-wide test
statistics we observe no correlation of the number of SNPs per
gene with pemp for any method. We observe an increase of genes
with very low pemp values caused by the actual association signal.
(TIFF)
Figure S3 Empirical p-values vs. uncontrolled p-values
(Type 1 Diabetes). For each gene the pemp is plotted against the
uncontrolled p-value (based on the gene-wide test statistic). Each
point represents a gene and is coloured according to the number of
SNPs assigned to a gene (n). Genes with few SNPs have pemp values
similar to the uncontrolled p-value and therefore cluster along the
diagonal. For genes with higher number of SNPs the distribution
depends on the method to combine test statistics.
(TIFF)
Figure S4 Distribution of the number of SNPs assigned
to genes. We assigned SNPs on the Affymetrix 500K genotyping
array to protein-coding genes. SNPs were assigned to a gene if they
are located within the transcribed region or within a 40 kilobase
flanking window around the transcribed region. In addition SNPs
in linkage disequilibrium (LD, r2.0.8) with these SNPs were
included.
(TIFF)
Figure S5 Effect of Linkage Disequilibrium (LD). Gene
ranks after assigning SNPs to genes based on genomic distance
only are plotted against gene ranks after assigning SNPs to genes
based on genomic distance and linkage disequilibrium (LD, r2.
0.8). The top 500 ranks are compared for CD and T1D and all
three methods to derive pemp-values.
(TIFF)
Figure S6 Effect of Population Stratification. Gene ranks
based on an armitage trend test are plotted against gene ranks
based on logistic regression and adjusting for two principal
components. The top 500 ranks are compared for CD and T1D
and all three methods to derive pemp-values.
(TIFF)
Table S1 Pairwise Spearman rank correlation for the
different methods to combine test statistics before and
after controlling for multiple hypothesis testing for
Crohn’s Disease. For the correlation the top 500 genes were
considered.
(DOC)
Table S2 Pairwise Spearman rank correlation for the
different methods to combine test statistics before and
after controlling for multiple hypothesis testing for Type
1 Diabetes. For the correlation the top 500 genes were
considered.
(DOC)
Table S3 Replicated Disease Genes for Type 1 Diabetes
(T1D) and their ranks for each method.
(DOC)
Table S4 The top 30 genes for Type 1 Diabetes (T1D)
ranked using the maxT method. Genes are ordered by
chromosome and genomic position; n denominates the number of
SNPs per gene. The last three columns show the corresponding
ranks for the three methods. italics: genes that are within the true
positive list.
(DOC)
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